NeuBase Therapeutics (NASDAQ:NBSE) Sees Significant Growth in Short Interest

NeuBase Therapeutics (NASDAQ:NBSE) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 108,000 shares, an increase of 23.7% from the September 30th total of 87,300 shares. Based on an average trading volume of 68,200 shares, the short-interest ratio is currently 1.6 days. Currently, 1.0% of the company’s shares are short sold.

NBSE traded down $0.08 during mid-day trading on Thursday, hitting $5.12. 38,200 shares of the stock were exchanged, compared to its average volume of 147,604. The firm’s fifty day moving average price is $4.97. NeuBase Therapeutics has a 1-year low of $1.60 and a 1-year high of $6.95.

NeuBase Therapeutics (NASDAQ:NBSE) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter. On average, research analysts anticipate that NeuBase Therapeutics will post -1.08 earnings per share for the current year.

A hedge fund recently bought a new stake in NeuBase Therapeutics stock. Heritage Wealth Advisors purchased a new stake in NeuBase Therapeutics (NASDAQ:NBSE) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,000 shares of the company’s stock, valued at approximately $54,000. Heritage Wealth Advisors owned approximately 0.06% of NeuBase Therapeutics at the end of the most recent reporting period. 1.90% of the stock is owned by institutional investors.

Several research firms recently issued reports on NBSE. ValuEngine lowered NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. HC Wainwright began coverage on NeuBase Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $14.00 target price on the stock. Finally, BTIG Research began coverage on NeuBase Therapeutics in a research note on Tuesday, September 24th. They set a “buy” rating and a $15.00 target price on the stock.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.

Read More: Federal Reserve

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with's FREE daily email newsletter.